Corcept gets FDA OK for first-in-class ovarian cancer drug Corcept shares surge on FDA approval of Lifyorli, a first-in-class selective glucocorticoid receptor antagonist for ovarian cancer.

#Corcept shares surge on #FDA approval of Lifyorli, a first-in-class selective glucocorticoid receptor antagonist for ovarian cancer.

Corcept Gains FDA Approval for Cancer Therapy Corcept received FDA approval on Mar 25, 2026; shares rose ~28% intraday and market cap expanded by ~$600m, accelerating commercial and strategic options for the company.

Corcept Gains FDA Approval for Cancer Therapy: Corcept received FDA approval on Mar 25, 2026; shares rose ~28% intraday and market cap expanded by ~$600m, accelerating commercial and strategic options for… 👈 Read full analysis #Corcept #FDAApproval #CancerTherapy #PharmaNews #HealthcareInnovation

Investors Unite in Class Action Against Corcept Therapeutics for Alleged Securities Fraud The Rosen Law Firm has initiated a class action lawsuit for investors of Corcept Therapeutics, seeking justice for alleged securities fraud affecting stock purchases between 2024-2025.

Investors Unite in Class Action Against Corcept Therapeutics for Alleged Securities Fraud #United_States #New_York #Securities_Fraud #Rosen_Law_Firm #Corcept

Pomerantz Law Firm Alerts Investors on Class Action Against Corcept Therapeutics Amid Losses Pomerantz Law Firm has filed a class action lawsuit against Corcept Therapeutics, alerting investors about potential losses. Key deadlines are approaching.

Pomerantz Law Firm Alerts Investors on Class Action Against Corcept Therapeutics Amid Losses #USA #New_York #Class_Action #Pomerantz #Corcept